Methoxyketamine (2-MeO-ketamine)
Methoxyketamine is a novel ketamine analogue research chemical in which a methoxy group is added to the ketamine scaffold (distinct from methoxetamine). It is a dissociative NMDA antagonist reported anecdotally to be weaker than ketamine, with no clinical data and unknown toxicology.
01 Overview
Methoxyketamine (typically 2-MeO-ketamine or related methoxy-substituted ketamines) appeared on the research-chemical market as a ketamine substitute. It retains the aryl-ketone dissociative scaffold of ketamine rather than the aryl-cyclohexanone-imine of methoxetamine, and is described anecdotally as less potent with a shorter, hazier effect.
Human pharmacology is unstudied. It plausibly shares ketamine's liabilities including urinary tract toxicity with heavy use and dependence, but with no data to quantify them and uncertain purity from grey-market suppliers.
02 Mechanism
Non-competitive NMDA receptor antagonist of the ketamine (arylcyclohexanone) class.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal (unverified) | 40–120 mg | Insufflated | Anecdotal only; reported weaker than ketamine, dose-response unknown. |
| Anecdotal oral (unverified) | 80–200 mg | Oral | Anecdotal only. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| DissociationKetamine-like detachment and anaesthesia at higher doses, reported milder. | unquantified | Anecdotal | |
| EuphoriaMood lift and giddiness reported at lower doses. | unquantified | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Urinary tract toxicity (presumed)By analogy with ketamine, heavy or chronic use may cause ulcerative cystitis and bladder damage. | Severe | Unknown, class risk | Unconfirmed | |
| Dependence potentialKetamine-type dissociatives can be habit-forming with binge patterns. | Moderate | Unknown, class risk | Unconfirmed |